Lonza: Announces Agreement To Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination.

30 Oct 2020 14:13

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19. cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site...

Attachments: